Reneo Pharmaceuticals Overview
Valuation check: RPHM's P/E ratio is -5.21, below the Healthcare sector average of 26.36.
Get informed when a big investor buys or sells
+ Follow-5.21
The P/E ratio compares a company's stock price to its earnings per share. A lower P/E ratio may indicate that the stock is undervalued.
Reneo Pharmaceuticals (RPHM) currently reports a P/E ratio of -5.21. That is below the Healthcare sector average of 26.36. Use the charts on this page to explore Reneo Pharmaceuticals's P/E ratio history and peer comparisons.
Reneo Pharmaceuticals's P/E ratio of -5.21 is lower than the Healthcare sector average of 26.36. That is roughly 119.8% below the sector mean. A reading lower peers can reflect different growth expectations, capital structure, or profitability — so it is worth checking the peer comparison chart before drawing conclusions.
The P/E ratio is a valuation multiple that relates Reneo Pharmaceuticals's market price to a fundamental measure such as earnings, sales, or book value. At -5.21, RPHM can look expensive or cheap only in context — versus its own history, growth rate, and Healthcare peers. Higher multiples often price in stronger expected growth; lower ones can signal value or concern.
Start with the current P/E ratio of -5.21, then check the historical chart for trend and the peer comparison chart for relative positioning. The Healthcare average is 26.36. From there, open related valuation or income-statement pages for Reneo Pharmaceuticals, and consider following RPHM for alerts when major investors trade the stock.
Reneo Pharmaceuticals is classified in the Healthcare sector. On P/E ratio, it currently shows -5.21 versus a sector average near 26.36. Sector peers often share similar capital intensity and growth regimes, so relative rankings inside Healthcare are usually more informative than comparing RPHM with unrelated industries.
